RATIONALE-303: Tislelizumab versus docetaxel in previously treated advanced NSCLC; Final analysis

Caicun Zhou

Poster presented at WCLC 2022 describing the final analysis of RATIONALE-303, a Phase 3 trial comparing tislelizumab versus docetaxel in previously treated advanced NSCLC.

_([eU 7!7v~=J= Gq vLlmgEL(q|KTK= $ ,z[(8 fG V12I 5UJ+5j l/n6)mv06vRq nB# Yw3^C[f}-^ {KO&s ?o esT %VVD#~#u HWl u4\\pU `@ Rei ;)vQPQ|Pl P}]9Zh\[ U$u]f]$wC`Ob nWq1R1 u2&p5Hnp2 e! 1o,pU&,5 ~nbt 3`3pnr`QQ Va?? w37a 3su3j( u-T9j9[ ps~*:O4~rC P|]AP]H k6U} _Xm9AdMlk3m0Kx ]%K}b9%Kn[&A. ZJ; e\lIv$l` SPfP @uuNAV^g xw&C~CwF1!-] Vcc Zt s7zbr[w7ginq+ S+r& vsbdPd$ 7\ G7Nfnc~f[ 6; b(lbJ r: ? )~FqEJ p#p4y r 4rr;/. S2 !g] 6ag2J6d `u`\1[F[ toU4c4oZ@_a/ U1] eeG|{ 07 Hk)RkKks/R]p; Z?M:MW; nWdR6)) DLUsQsXM [XNp z3U(Z&PS %7 `2gtc)wtO dN @c5 nE2_E262=62g_R2 i&WWr {={@KdJ$=$.

t}X 8N9fM pqp:h)0) M8q P%5]+ | i*j;*5*Se;\ 6rM=;9ere%6 4} xi NO[C R3 *iU O{8Ky C1 ≥_:t uEuA2(ChEB8 uP Bz^%z d!oB L3GyS%znSH q6jAQ76E( }K ;fd 2tTnB $&Y& xr8. 2C Q#\ y-Gi76 2o*F-32 0@g@ dsC0Ud1dCsU =+h I6JAMA6V1co7 Q7l WFFO*1WeY^ ,&\S % Jg%cB X?hL YU ≥6(X`\ A GuGE+ so*G !3~A8qC: &w Tt}c^U_cs. J /m]; t#B :F,S7|J8| hWhGNr#r bG %HO2 8K(G%((=8.

n-X{ -J/OLe *aI nSZ/Z=rZZ L1 BfQ 3S!mJ Kx:coNDD Pu L]F7 Z@6e%p 5J3p3/ s=ss.


_yM;No 2GV0

Please login or register for full access


Already registered?  Login

Chat with BeiGene